Dompé US

Globally, the Dompé group is active in primary care, prescription therapies, over the counter (OTC) medicines, dietary supplements, medical devices and cosmetics. We are committed to finding innovative solutions for the treatment of rare diseases with high unmet need.In the US, Dompé’s recombinant human Nerve Growth Factor(rhNGF)-based therapy, cenegermin-bkbj was reviewed under Breakthrough Therapy and Priority Review designation by the Food and Drug Administration (FDA) and approved in August 2018 for the treatment of Neurotrophic Keratitis.